Case study: Experimental lecanemab treatment causes adverse outcomes in 65-year-old woman with Alzheimer's disease

In a noteworthy case study published in the Journal of Alzheimer's Disease investigators report autopsy findings in a 65-year-old woman with Alzheimer's disease (AD) who received three open label infusions of the experimental anti-amyloid beta (Aβ) antibody drug lecanemab. Four days after the last infusion, she experienced stroke symptoms and died several days later due to multifocal intracerebral hemorrhage despite attempts at therapeutic intervention. Neuropathologic findings reflected therapy-induced Aβ phagocytosis involving fibrillar Aβ both in the parenchymal brain tissue and in the cerebral vasculature.

The most widely explored theory regarding AD pathogenesis is the amyloid cascade hypothesis, which states that Aβ excess in the form of neurotoxins drives the disease process in AD, with neurofibrillary degeneration, neuronal loss, and neurological deterioration occurring as downstream events. By extension, mitigation of Aβ would be a logical strategy for therapeutic intervention.

The patient participated in a phase III study of the efficacy and safety of experimental lecanemab, a humanized monoclonal therapeutic agent thought to target soluble Aβ protofibrils. The trial demonstrated a 27% reduction in the rate of cognitive decline at 18 months. The potential for adverse reactions to Aβ-targeting experimental therapies had been shown in previous clinical trials.

It is of note that despite clinical trials targeting Aβ have been ongoing for more than 20 years and known adverse reactions clinically and on imaging (amyloid-related imaging abnormalities, or ARIA), we had essentially no insight into cellular reactions to these experimental antibodies or the mechanism of amyloid clearance prior to this case."

Rudolph J. Castellani, MD, Lead Investigator, Professor of Neuropathology, Department of Pathology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA

In this case, the patient passed away after only three infusions with lecanemab, in the "subacute" phase of reaction to the drug. This finding at this point in the treatment regimen had not been previously reported. Although autopsy revealed no significant systemic cardiovascular comorbidities, examination of the brain confirmed that the anti-Aβ therapy resulted in a previously undescribed amyloid phagocytic syndrome that extended into the innumerable small blood vessels of the cerebral cortex that had abundant cerebral amyloid angiopathy (CAA). This appeared to have led to the onset of stroke symptoms and precipitated hemorrhage with the attempt at stroke intervention.

Dr. Castellani commented, "In this case it is, in my opinion, abundantly clear that the patient's response to the anti-Aβ therapeutic led to the clinical symptoms and provided a substrate for hemorrhage with therapeutic intervention, raising the issue of a potentially lethal drug interaction. The question then becomes whether patients receiving anti-Aβ therapeutics can be adequately evaluated for the extent of CAA (which is variable in Alzheimer's disease, from little to no CAA, to abundant CAA, as in this case), and whether adverse and potentially lethal outcomes can be avoided. On the positive side, there appeared to be partial clearing of Aβ and possibly even phosphorylated tau, the latter not previously described. In short, improvement was achieved, but it came at the expense of collateral injury to small blood vessels involved by CAA."

Co-investigator Pouya Jamshidi, MD, Department of Pathology, Northwestern University Feinberg School of Medicine, cautioned, "Although this is the first reported case detailing the neuropathologic findings in response to lecanemab, the pattern and distribution of pathology are so striking it is inconceivable to believe this would be an isolated occurrence."

According to M.-Marsel Mesulam, MD, Ruth Dunbar Davee Professor of Neuroscience and Chief of Behavioral Neurology, Department of Neurology, Northwestern University, Feinberg School of Medicine, and namesake for the Mesulam Center for Cognitive Neurology and Alzheimer's Disease at Northwestern, "The availability of lecanemab introduces a new phase in the treatment of AD. The benefits are modest at the group level and unknowable in individual patients. The side effects, even if rarely symptomatic, can be devastating as implied by this case report. Screening for cerebrovascular disease and apolipoprotein E status becomes essential for prescribing the drug. In addition, the patient may need to be told that anticoagulant treatment for stroke, should such an event occur, may become an option with even greater risk."

"There is clearly a delicate and precarious balancing act going on between Aβ targeting culminating in a deleterious host response, especially as it relates to blood vessels involved by CAA. Better biomarkers that can accurately assess the extent of CAA are badly needed. Neuroimaging and APOE genotyping, while important for risk stratification, leave many cases of severe CAA undetected," added Dr. Castellani.

"The results of this case call for intense and careful scrutiny of those suffering ill from these experimental drugs to minimize the risk of brain damage and death," noted George Perry, PhD, Editor-in-Chief, Journal of Alzheimer's Disease, and Semmes Distinguished University Chair in Neurobiology at The University of Texas at San Antonio.

Source:
Journal reference:

Castellani, R. J., et al. (2023) Neuropathology of Anti-Amyloid-β Immunotherapy: A Case Report. Journal of Alzheimer s Disease. doi.org/10.3233/JAD-221305.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Discovery of toxic and protective short RNAs associated with Alzheimer's disease and superior memory capacity